- Published at
- by globenewswire.com
neutral
neutral
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
-- Received FDA approval of IMCIVREE™ (setmelanotide), the first-ever therapy for chronic weight management in patients with obesity due to POMC, PCSK1 or...